{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T05:12:52Z","timestamp":1792127572490,"version":"4.4.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2005,5,1]],"date-time":"2005-05-01T00:00:00Z","timestamp":1114905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2005,5]]},"DOI":"10.1016\/j.clinthera.2005.04.011","type":"journal-article","created":{"date-parts":[[2005,6,23]],"date-time":"2005-06-23T07:21:43Z","timestamp":1119511303000},"page":"568-577","source":"Crossref","is-referenced-by-count":27,"title":["A comparison of the clinical efficacy of pheniramine maleate\/naphazoline hydrochloride ophthalmic solution and olopatadine hydrochloride ophthalmic solution in the conjunctival allergen challenge model"],"prefix":"10.1016","volume":"27","author":[{"given":"Jack V.","family":"Greiner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira J.","family":"Udell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2005.04.011_bib1","series-title":"Allergic Diseases of the Eye","first-page":"108","article-title":"Acute allergic conjunctivitis","author":"Collum","year":"2000"},{"key":"10.1016\/j.clinthera.2005.04.011_bib2","first-page":"96","article-title":"Physiological and pharmacological evidence for the regulation of permeability","volume":"45","author":"Grega","year":"1986"},{"key":"10.1016\/j.clinthera.2005.04.011_bib3","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1067\/mai.2000.111238","article-title":"Allergic and immunologic disorders of the eye. Part II: Ocular allergy","volume":"106","author":"Bielory","year":"2000","journal-title":"J Allergy Clin Immunol"},{"issue":"Suppl 6","key":"10.1016\/j.clinthera.2005.04.011_bib4","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1046\/j.1365-2222.1998.0280s6008.x","article-title":"Why is allergy increasing?\u2014Environmental factors","volume":"28","author":"Davies","year":"1998","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.clinthera.2005.04.011_bib5","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/S0952-7915(01)00282-5","article-title":"Why are allergies increasing?","volume":"13","author":"Ring","year":"2001","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.clinthera.2005.04.011_bib6","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1001\/archopht.1990.01070030090035","article-title":"Conjunctival allergen challenge. A clinical approach to studying allergic conjunctivitis","volume":"108","author":"Abelson","year":"1990","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.clinthera.2005.04.011_bib7","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1016\/S0149-2918(03)80200-X","article-title":"A placebo-controlled comparison of ketotifen fumarate and nedocromil sodium ophthalmic solutions for the prevention of ocular itching with the conjunctival allergen challenge model","volume":"25","author":"Greiner","year":"2003","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2005.04.011_bib8","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/S0149-2918(02)80027-3","article-title":"Comparison of the efficacy of combined fluticasone propionate and olopatadine versus combined fluticasone propionate and fexofenadine for the treatment of allergic rhinoconjunctivitis induced by conjunctival allergen challenge","volume":"24","author":"Lanier","year":"2002","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2005.04.011_bib9","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0149-2918(02)85042-1","article-title":"Randomized, double-masked, placebo-controlled comparison of the efficacy of emedastine difumarate 0.05% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the human conjunctival allergen challenge model","volume":"24","author":"D'Arienzo","year":"2002","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2005.04.011_bib10","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s11882-003-0100-z","article-title":"Conjunctival allergen challenge: Models in the investigation of ocular allergy","volume":"3","author":"Abelson","year":"2003","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.clinthera.2005.04.011_bib11","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0002-9394(98)00044-0","article-title":"Combined analysis of two studies using the conjunctival allergen challenge model to evaluate olopatadine hydrochloride, a new ophthalmic antiallergic agent with dual activity","volume":"125","author":"Abelson","year":"1998","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.clinthera.2005.04.011_bib12","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1001\/archopht.1990.01070060068051","article-title":"Effects of Vasocon-A in the allergen challenge model of acute allergic conjunctivitis","volume":"108","author":"Abelson","year":"1990","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.clinthera.2005.04.011_bib13","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S1081-1206(10)62814-1","article-title":"Evaluation of olopatadine, a new ophthalmic antiallergic agent with dual activity, using the conjunctival allergen challenge model","volume":"81","author":"Abelson","year":"1998","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.clinthera.2005.04.011_bib15","series-title":"Physicians' Desk Reference for Ophthalmic Medications","year":"2005"},{"key":"10.1016\/j.clinthera.2005.04.011_bib16","series-title":"Patanol, olopatadine hydrochloride 0.1% ophthalmic solution [package insert]","year":"2003"},{"key":"10.1016\/j.clinthera.2005.04.011_bib17","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/0091-6749(88)90094-2","article-title":"Antiallergic activity of H1-receptor antagonists assessed by nasal challenge","volume":"82","author":"Bousquet","year":"1988","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.clinthera.2005.04.011_bib18","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/S0091-6749(99)70226-5","article-title":"Onset and duration of action of levocabastine nasal spray in atopic patients under nasal challenge conditions","volume":"103","author":"Corren","year":"1999","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.clinthera.2005.04.011_bib19","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/S0091-6749(96)80196-5","article-title":"Topical azelastine reduces eosinophil activation and intercellular adhesion molecule-1 expression on nasal epithelial cells: An antiallergy activity","volume":"98","author":"Ciprandi","year":"1996","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.clinthera.2005.04.011_bib20","series-title":"Manual of Operations","author":"Early Treatment Diabetic Retinopathy Study","year":"1980"},{"key":"10.1016\/j.clinthera.2005.04.011_bib21","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/S0149-2918(01)80106-5","article-title":"Evaluation of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and azelastine hydrochloride 0.05% ophthalmic solution in the conjunctival allergen challenge model","volume":"23","author":"Spangler","year":"2001","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2005.04.011_bib22","series-title":"Principles and Practices of Ophthalmology","first-page":"781","article-title":"Allergic and toxic reactions","author":"Abelson","year":"2000"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291805000676?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291805000676?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,6,21]],"date-time":"2018-06-21T01:34:03Z","timestamp":1529544843000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291805000676"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,5]]}},"alternative-id":["S0149291805000676"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2005.04.011","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2005,5]]}}}